Digoxin Toxicity and Use of Digoxin Immune Fab. Insights From a National Hospital Database.

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 357-364

  Hauptman, Paul J ^a   Blume, Steven W ^b   Lewis, Eldrin F ^c   Ward, Suzanne ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EVIDERA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BTG International Inc   (United States)

Author keywords

Antidote; Digoxin; Outcomes; Toxicity

Indexed keywords

ACTIVATED CARBON; ATROPINE; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; LIDOCAINE; POTASSIUM; ANTIDOTE; CARDIOTONIC AGENT; DIGOXIN ANTIBODIES FAB FRAGMENTS; IMMUNOGLOBULIN F(AB) FRAGMENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DEFIBRILLATION; DIGITALIS INTOXICATION; DRUG COST; DRUG USE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL MORTALITY; HUMAN; HYPERKALEMIA; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELECTION BIAS; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ECONOMICS; FACTUAL DATABASE; HOSPITALIZATION; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANTIDOTES; CARDIOTONIC AGENTS; DATABASES, FACTUAL; DIGOXIN; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84962045044     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.01.011     Document Type: Article

References (25)

1. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
2. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014, 64:e1-e76.
3. Hussain Z., Swindle J., Hauptman P.J. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006, 12:343-346.
4. Ziff O.J., Lane D.A., Samra M., et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015, 351:h4451.
5. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003, 289:871-878.
6. Shah M., Avgil Tsadok M., Jackevicius C.A., Essebag V., Behlouli H., Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol 2014, 114:401-406.
7. Chan K.E., Lazarus J.M., Hakim R.M. Digoxin associates with mortality in ESRD. J Am Soc Nephrol 2010, 21:1550-1559.
8. Yang E.H., Shah S., Criley J.M. Digitalis toxicity: a fading but crucial complication to recognize. Am J Med 2012, 125:337-343.
9. Lapostolle F., Borron S.W., Verdier C., et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med 2008, 34:1448-1453.
10. Lapostolle F., Borron S.W., Verdier C., et al. Digoxin-specific fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med 2008, 36:3014-3018.
11. Schaeffer T.H., Mlynarchek S.L., Stanford C.F., et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab-a retrospective study. J Am Osteopath Assoc 2010, 110:587-592.
12. Premier healthcare informatics. Premier capabilities and hospital characteristics. Charlotte, NC: Premier, Inc., 2009.
13. Allison P.D. Fixed Effects Regression Methods for Longitudinal Data Using SAS 2005, SAS Institute, Inc., Cary, NC.
14. Woolridge J. Econometric Analysis of Cross Section and Panel Data 2010, MIT Press, Cambridge, MA.
15. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533. The Digitalis Investigation Group.
16. Ouyang A.J., Lv Y.N., Zhong H.L., et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 2015, 115:901-906.
17. Vamos M., Erath J.W., Hohnloser S.H. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015, 36:1831-1838.
18. Haynes K., Heitjan D., Kanetsky P., Hennessy S. Declining public health burden of digoxin toxicity from 1991 to 2004. Clini Pharm Ther 2008, 84:90-94.
19. See I., Shehab N., Kegler S.R., Laskar S.R., Budnitz D.S. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circ Heart Fail 2014, 7:28-34.
20. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131:e29-e322.
21. Hauptman P.J., McCann P., Ramirez Romero J.M., Mayo M. Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Int Med 2013, 173:1552-1554.
22. Adams K.F., Gheorghiade M., Uretsky B.F., Patterson J.H., Schwartz T.A., Young J.B. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002, 39:946-953.
23. Gandhi A.J., Vlasses P.H., Morton D.J., Bauman J.L. Economic impact of digoxin toxicity. Pharmacoeconomics 1997, 12:175-181.
24. DiDomenico R.J., Walton S.M., Sanoski C.A., Bauman J.L. Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity. J Cardiovasc Pharmacol Ther 2000, 5:77-85.
25. Kirrane B.M., Olmedo R.E., Nelson L.S., Mercurio-Zappala M., Howland M.A., Hoffman R.S. Inconsistent approach to the treatment of chronic digoxin toxicity in the United States. Hum Exp Toxicol 2009, 28:285-292.